It was a mixed day for healthcare stocks, as gains for UnitedHealth and Eli Lilly counterbalanced losses for Centene and Thermo Fisher.
BioNTech leapt higher following news of a new deal with Bristol Myers Squibb to develop BioNTech's BNT327 candidate drug for cancer commercially.
Amgen fell slightly on the day. The drug developer said interim results from a Phase 3 trial showed its Imdelltra drug reduced the risk of death and other benefits for patients with small cell lung cancer.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 02, 2025 16:54 ET (20:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.